EFFECT OF ADDING IDELALISIB TO FRONTLINE OFATUMUMAB PLUS EITHER CHLORAMBUCIL OR BENDAMUSTINE IN LESS FIT PATIENTS WITH CLL: PRELIMINARY RESULTS FROM THE NCRI RIALTO TRIAL.
Pettitt, A.R., Kalakonda, N., Polydoros, F., Bickerstaff, M., Menon, G., Coupland, S.E., Oates, M., Lin, K., Pocock, C., Jenkins, S., Schuh, A., Wandroo, F., Rassam, S., Duncombe, A.S., Jenner, M., CeVolume:
35
Language:
english
Journal:
Hematological Oncology
DOI:
10.1002/hon.2437_77
Date:
June, 2017
File:
PDF, 117 KB
english, 2017
File converter
More search results
More benefits 
